News

“We’re extremely proud and fortunate to have Rusty join our team,” said Page Erickson, chairman of the board of directors. “As Celerus continues to grow and achieve profitability,

Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty technology, as well as on-going investment in product development and clinical studies. Johnson & Johnson

The company has also announced that Al Kraus has been elected to chairman of the board. William Miller has stepped down as chairman after two years of service.

The collaboration is focused on identifying biomarkers in the field of systemic lupus erythematosus for clinical diagnostic purposes associated with the clinical development of Orencia, a Bristol-Myers Squibb

Mr McCormick succeeds Patrick Spangler, who has resigned as senior vice president and CFO, effective January 19, 2009. Most recently, Mr McCormick served as vice president of corporate

CPP-109 is Catalyst’s tablet formulation of vigabatrin being developed as a treatment for cocaine and methamphetamine addiction, as well as other addictions and obsessive-compulsive disorders. The randomized, double-blind,

Dr Caudrelier joined Theratechnologies in August 2007 and worked actively in the completion of the Phase III clinical program evaluating tesamorelin in HIV-associated lipodystrophy. Dr Caudrelier’s responsibilities will

Abbott’s 2009 outlook includes the acquisition of Advanced Medical Optics (AMO) as announced today (see separate news release). Abbott expects the AMO transaction to be neutral to ongoing

The single-dose, open-label study is designed to assess the pharmacokinetics, safety and tolerability of a gluteal injection of this risperidone formulation in approximately 26 patients diagnosed with chronic,